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Inhibiting HIV-1 Entry: Discovery of D-Peptide
Inhibitors that Target the gp41 Coiled-Coil Pocket
1995; Lu et al., 1995) as seen in the X-ray crystal struc-
ture of a protease-resistant core of gp41 (Chan et al.,
1997; Tan et al., 1997; Weissenhorn et al., 1997). It is
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unclear whether hairpin formation occurs before, or si-Whitehead Institute for Biomedical Research
multaneously with, the actual fusion of the two bilayers.Department of Biology
The trimer-of-hairpins structure is a common featureMassachusetts Institute of Technology
of diverse viral membrane fusion proteins (Singh et al.,Nine Cambridge Center
1999, and references therein). In gp41, a central three-Cambridge, Massachusetts 02142
stranded coiled coil (formed by the N-terminal regions
of gp41) is surrounded by helices derived from the
C-terminal end of the gp41 ectodomains, packed in anSummary
antiparallel manner around the outside of the coiled coil
(Figure 1, inset). Peptides corresponding to these re-The HIV-1 gp41 protein promotes viral entry by mediat-
gions of gp41 are referred to as N-peptides and C-pep-ing the fusion of viral and cellular membranes. A promi-
tides, respectively.nent pocket on the surface of a central trimeric coiled
Synthetic C-peptides are potent inhibitors of HIV-1coil within gp41 was previously identified as a potential
infection. These inhibitors, such as C34 or DP178 (seetarget for drugs that inhibit HIV-1 entry. We designed
Figure 1 legend), inhibit HIV-1 infection and syncytiaa peptide, IQN17, which properly presents this pocket.
formation at nanomolar concentrations in cell cultureUtilizing IQN17 and mirror-image phage display, we
experiments (Jiang et al., 1993; Wild et al., 1994; Lu etidentified cyclic, D-peptide inhibitors of HIV-1 infection
al., 1995; Chan et al., 1998; Rimsky et al., 1998). Therethat share a sequence motif. A 1.5 AÊ cocrystal struc-
is substantial evidence to indicate (see Discussion) thatture of IQN17 in complex with a D-peptide, and NMR
C-peptides act in a dominant-negative manner (Her-studies, show that conserved residues of these inhibi-
skowitz, 1987) by binding to the transiently exposedtors make intimate contact with the gp41 pocket. Our
coiled-coil N-peptide region in the prehairpin intermedi-studies validate the pocket per se as a target for drug
ate (Figure 1).development. IQN17 and these D-peptide inhibitors
A phase I clinical trial showed that DP178 (recentlyare likely to be useful for development and identifica-
renamed T-20) has an antiviral effect when injected intotion of a new class of orally bioavailable anti-HIV drugs.
infected individuals (Kilby et al., 1998). This result pro-
vides compelling evidence that the prehairpin intermedi-Introduction
ate is a useful target for anti-HIV therapy in humans.
However, very large amounts of T-20 (z200 mg/day) areCurrently, anti-HIV-1 combination drug therapy only tar-
required to observe an antiviral effect, whereas nanomo-gets HIV-1 protease and reverse transcriptase. Re-
lar concentrations are efficacious in cell culture. Thus,cently, there has been an influx of structural and func-
bioavailability issues, presumably including rapid pro-tional information on the HIV-1 membrane fusion process
teolytic degradation, need to be addressed before(Chan and Kim, 1998; Kwong et al., 1998; Berger et al.,
C-peptides can be widely used as therapeutic agents.1999; and references therein). These studies have raised
It would be highly desirable if an orally bioavailablehopes that viral entry is another part of the HIV-1 life
drug could be identified that prevents HIV-1 entry bycycle that can be successfully inhibited.
binding to the prehairpin intermediate of gp41. There are
Infection of cells by HIV-1 requires fusion of the cellu-
many hurdles to the development of orally bioavailable
lar and viral membranes, a process mediated by the
drugs. A major issue is that oral bioavailability generally
viral envelope glycoprotein complex (gp120/gp41) and requires a molecular weight of less than 1000 Da. (In
cell surface receptors on the target cell. A working model comparison, T-20 and C34 have molecular weights
for this entry process (Figure 1) involves multiple steps greater than 4000 Da). Based on the crystal structure
that have been delineated through numerous studies of the gp41 core, the prehairpin intermediate is expected
(for review, Chan and Kim, 1998). Binding of gp120/gp41 to contain three prominent, symmetry-related pockets
to cellular receptors (CD4 and a chemokine coreceptor on the surface of the central trimeric coiled coil (Figure
such as CCR-5 or CXCR-4) induces a conformational 1). Each pocket has an internal volume of roughly 400 AÊ 3
change in the envelope glycoprotein. A transient species and could be filled by a molecule with a molecular weight
results, termed the prehairpin intermediate, in which of approximately 500 Da, raising the possibility that it
gp41 exists as a membrane protein simultaneously in could be targeted by small-molecule drugs.
both the viral and cellular membranes (Chan and Kim, For several additional reasons, these gp41 pockets
1998; Furuta et al., 1998; Jones et al., 1998; Munoz- are expected to be attractive drug targets (Chan et al.,
Barroso et al., 1998). The prehairpin intermediate re- 1997, 1998). First, mutagenesis studies indicate that the
solves to a trimer-of-hairpins structure that likely repre- N-peptide residues forming the pocket are critical for
sents the fusion-active state of gp41 (Blacklow et al., membrane fusion (Dubay et al., 1992; Cao et al., 1993;
Chen et al., 1993; Wild et al., 1994; Weng and Weiss,
1998; D. C. Chan and P. S. K., unpublished results).* To whom correspondence should be addressed (e-mail: tocio@
wi.mit.edu). Second, studies of C34 variants show that C34 inhibitory
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activity depends on its ability to bind to the pocket (Chan
et al., 1998). Third, therapeutic agents that target this
pocket would likely be relatively elusive to the emer-
gence of resistant viral strains because (1) residues com-
prising this region are highly conserved among HIV-1
isolates (see Figure 1 legend), and (2) the segment of
mRNA encoding these residues is part of the structured
RNA region of the Rev-responsive element (RRE) that
is important for Rev response (Malim et al., 1989; Zapp
and Green, 1989). Indeed, C-peptides that do not con-
tain pocket-binding residues, such as T-20, are more
vulnerable to the emergence of resistant virus than are
C-peptides that contain pocket-binding residues, such
as T649 (Rimsky et al., 1998).
Despite the expectation that the pocket is a promising
drug target, there is no direct evidence that molecules
binding solely to the pocket (i.e., and not simultaneously
to other regions of the gp41 coiled coil) can inhibit HIV-1
infection. It would therefore be desirable to screen a
library of compounds for their pocket binding ability.
The obvious target for such screens is the N-peptide
region that comprises the central trimeric coiled coil of
the gp41 crystal structure. Unfortunately, in the absence
of C-peptides, N-peptides aggregate (Lu et al., 1995,
and references therein; Lu and Kim, 1997), presumably
due to the hydrophobic nature of the grooves into which
the C-helices pack. A more soluble but accurate repre-
sentation of the pocket is required for drug screening.
We have overcome the aggregation problem by fusing
the corresponding gp41 residues to a soluble trimeric
coiled coil. The resulting peptide, IQN17, is expected to
properly display the pocket of gp41 and thus should be
useful for the discovery of compounds that inhibit HIV-1
entry.
Indeed, we have used IQN17 and a previously devel-
oped mirror-image phage display method (SchumacherFigure 1. Model of HIV Membrane Fusion and Structure of the gp41
et al., 1996) to identify peptides composed of D-aminoCore
acids (which are therefore insensitive to proteolytic deg-Schematic representation of a working model for HIV membrane
radation) that bind to the hydrophobic pocket of gp41,fusion (for review, Chan and Kim, 1998). In the native state of the
trimeric gp120/gp41 complex (ªNativeº), the fusion peptide and as shown in NMR studies and a 1.5 AÊ X-ray cocrystal
N-peptide regions of gp41 are not exposed. Following interaction structure. These D-peptides inhibit gp41-mediated cell±
with cellular receptors (CD4 and coreceptor), a conformational cell fusion and HIV-1 infection, validating the pocket
change results in formation of the transient prehairpin intermediate as a target for drug development. The D-peptides may
(ªPre-Hairpinº), in which the fusion peptide regions (red lines) are
also serve as therapeutic or prophylactic agents, or asinserted into the cell membrane and the coiled coil of the N-peptide
leads for the development of such agents, for combatingregion of gp41 (indicated as ªNº) is exposed. However, the C-peptide
region of gp41 (indicated as ªCº) is constrained and unavailable for HIV infection. Finally, as pocket-binding molecules, the
interaction with the coiled coil. Thus, exogenous C-peptides can D-peptides can be used in competitive screens to iden-
bind to the prehairpin intermediate and inhibit fusion in a dominant- tify small-molecule drug candidates with similar inhibi-
negative manner (ªInhibitedº). In the absence of inhibitors, the pre- tory capabilities.
hairpin intermediate resolves to the hairpin structure and membrane
fusion results (ªHairpin/Fusionº), although it is not known whether
Resultshairpin formation precedes membrane fusion per se. The C-peptides
discussed in this paper (and corresponding residues in gp41, num-
bered according to their position in gp160 of the HXB2 HIV-1 strain) IQN17
are as follows: C34 [628±661]; DP178, also called T-20 [638±673]; Our focus is on the hydrophobic pocket of the N-peptide
and T649 [628±663]. Adapted from Chan and Kim (1998). coiled-coil region of gp41 (Figure 1, inset). A small mole-
The inset depicts the 2.0 AÊ X-ray crystal structure of N36/C34, a
cule that binds to this pocket might be expected topeptide version of the HIV-1 gp41 core (Chan et al., 1997). Three
central N-peptides form a coiled coil, shown here as a surface repre-
sentation, and three helical C-peptides pack along conserved
grooves on the surface of the coiled-coil trimer. There are three Lys-574, Leu-576, and Gln-577 of HXB2. These 11 residues are
symmetry-related hydrophobic pockets on the surface of the N-pep- completely conserved in 158 of 202 fully sequenced M group HIV-1
tide coiled coil (shaded). The pocket region is highly conserved strains (HIV Sequence Database [1998/1999 alignments], Los
among HIV-1 isolates. There are 11 residues that comprise the lining Alamos National Laboratory, http://hiv-web.lanl.gov). Of the re-
of the hydrophobic pocket (see Figure 7 of Chan et al., 1997): Leu- maining 44 isolates, 33 possess only a single conservative methio-
565, Leu-566, Leu-568, Thr-569, Val-570, Trp-571, Gly-572, Ile-573, nine substitution for Leu-565.
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act in a dominant-negative manner, analogous to the
synthetic C-peptides, inhibiting formation of the fusion-
active structure (Chan et al., 1997). In the absence of
C-peptides, N-peptides aggregate (Lu et al., 1995, and
references therein; Lu and Kim, 1997) and therefore are
not effective for screening small molecules.
We have designed a molecule, denoted IQN17, in
which a soluble trimeric coiled coil (GCN4-pIQI; Eckert
et al., 1998) is fused to the portion of the N-peptide that
comprises the gp41 hydrophobic pocket (Figure 2A).
Analyses of the X-ray crystal structures of GCN4-pIQI
(Eckert et al., 1998) and the N36/C34 core of gp41 (Chan
et al., 1997) indicate that the superhelical parameters
(Crick, 1953; Harbury et al., 1995) of the two coiled coils
are similar. Thus, structural perturbations resulting from
creation of the chimera are expected to be minimal.
We initially constructed a peptide in which the first
29 residues of GCN4-pIQI were fused to the last 17 resi-
dues of N36 (there is a 1 residue overlap between the
two regions, making the peptide 45 residues long). This
peptide did not form a specific trimeric species as deter-
mined by sedimentation equilibrium experiments, but
instead formed higher-order aggregates (D. M. E. and
P. S. K., unpublished results). We therefore made three
surface residue mutations, which were expected to in-
crease solubility, in the GCN4-pIQI region of the molecule
(Figure 2A). The resulting peptide, IQN17, is fully helical,
as demonstrated by circular dichroism spectroscopy
(Figure 2B), and is a soluble trimeric species as deter-
mined by sedimentation equilibrium experiments (Fig-
ure 2C).
Mirror-Image Phage Display
D-peptides that bind to a target protein of interest can
be identified through mirror-image phage display (Figure
3A; Schumacher et al., 1996). The desired target is syn-
thesized chemically with D-amino acids, resulting in a
product that is the mirror image of the naturally occurring
(L-amino acid) form. This D-target is then used to screen
phage expressing a peptide library on one of the phage
coat proteins, yielding specific phage clones with L-pep-
tide sequences that bind to the D-target. The mirror
images of the phage-expressed L-peptide sequences are
chemically synthesized with D-amino acids. By symme-
try, these D-peptides should bind to the natural (L-amino
acid) form of the target. This technique has been used
to identify D-peptides that bind to the SH3 domain of
c-Src (Schumacher et al., 1996). By using IQN17 in mir-
Figure 2. IQN17: Soluble, Trimeric Presentation of the gp41 Pocketror-image phage display, D-peptides that bind to the
(A) Helical wheel diagram of IQN17. The 17 residues indicated inpocket of gp41, and are therefore potential inhibitors of
blue are from gp41 (residues 565±581 of HXB2 gp160). The residuesHIV-1 infection, can be identified.
in black are from GCN4-pIQI, and the residues in red correspond toThe mirror image of IQN17 (denoted D-IQN17) was three surface substitutions in the GCN4-pIQI region, made to in-
chemically synthesized using D-amino acids (see Exper- crease solubility. The boxed residue represents the junction, at a
imental Procedures). As expected, D-IQN17 has a circu- leucine (in a ªgº position of the coiled coil) that is shared between
GCN4-pIQI and gp41.lar dichroism spectrum that is of opposite sign to that
(B) Circular dichroism spectrum of a 10 mM solution of IQN17 in PBSobserved for the L-amino acid version (D. M. E. and
(pH 7.4), 48C. IQN17 is fully helical, with an approximate ellipticity ofP. S. K., unpublished results). The N terminus of IQN17
236,000 deg cm2 dmol21 at 222 nm.
was biotinylated to allow immobilization on streptavidin- (C) Sedimentation equilibrium data of IQN17 at 20 mM in PBS (pH
coated plates for phage panning. A three±amino acid 7.0). Data are plotted as ln(absorbance) versus half the square of
linker (Gly-Lys-Gly) containing an L-lysine was placed the radius from the axis of rotation. The slope of the data is propor-
tional to the molecular mass of the peptide oligomer. Continuousbetween the biotin and IQN17. The L-lysine residue pro-
lines indicate the expected slopes for the different oligomeric states.vided a trypsin recognition site, so that bound phage
IQN17 is a discrete trimer under these conditions.could be eluted by addition of trypsin, rather than by a
Cell
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Figure 3. Mirror-Image Phage Display Using D-IQN17 as a Target
(A) Schematic of the mirror-image phage display method (Schumacher et al., 1996) applied to the gp41 pocket. IQN17 is synthesized with
D-amino acids to generate a mirror image of the gp41 pocket. A phage-displayed peptide library is subjected to several rounds of selection,
and phage that bind to D-IQN17 are sequenced. After testing for specific binding, the mirror images of the phage-expressed peptides are
chemically synthesized with D-amino acids and tested for anti-HIV-1 activity.
(B) Test for pocket-specific binding phage. Individual phage clones are screened for binding to wells containing: (i) D-IQN17, (ii) D-IQN17[G572W],
(iii) D-GCN4-pIQI9, and (iv) no target. In this schematic, the GCN4-pIQI9 region of the molecule is depicted in black, and the HIV-1 gp41 region
is depicted in white; the G572W mutation is indicated with an ªX.º D-GCN4-pIQI9 is a D-amino acid version of GCN4-pIQI (Eckert et al., 1998)
that contains the same surface mutations as IQN17. The G572W substitution in D-IQN17[G572W] introduces a large protrusion into the gp41
pocket. Phage are considered pocket-specific binders if they bind appreciably to wells containing IQN17, but not to the other wells. Representa-
tive data are shown for pocket-specific binding phage (φ10-p1 and φ10-p5) and nonspecific phage (φ10-p8 and φ10-p9).
(C) D-peptide sequences. Peptides corresponding to the mirror images of the peptides expressed on pocket-specific phage were synthesized
with D-amino acids. Four conserved residues among the ten positions that were randomly encoded in the phage library, as well as two Cys
residues that form an intramolecular disulfide bond to generate a cyclic peptide, define a consensus sequence. Flanking residues from the
gene III phage protein were added at the N termini (GA) and C termini (AA) to more closely represent the phage-displayed peptides. In addition,
lysine residues were added at the N termini of some peptides to increase solubility (peptides with two or four additional lysines are denoted
with the suffixes 22K or 24K, respectively; see text). The termini of all peptides were blocked (Ac, acetyl; NH2, amide).
nonspecific elution procedure such as acid addition (cf. of panning, 12 IQN17-specific phage were identified and
labeled φ10-p1 through φ10-p12 (see ExperimentalWrighton et al., 1996).
Phage that bind to D-IQN17 might bind to any region Procedures). Nine of the 12 phage clones are pocket-
specific binders, with some showing over 1000-foldof this target. Our interest was to identify those phage
that bind only to the gp41 pocket region. Phage that more binding to D-IQN17 than to the controls (Figure 3B).
In addition, eight of these nine contain the consensusbound specifically to D-IQN17 (i.e., not to wells that
lacked the target) were therefore further tested against sequence CXXXXXEWXWLC (Figure 3C).
a panel of molecules lacking the target pocket structure
(Figure 3B). Phage were considered to be pocket spe- Inhibition of Membrane Fusion
D-peptides corresponding to the mirror images of thecific if they bound to D-IQN17 but not to D-GCN4-pIQI9
or D-IQN17(G572W). D-GCN4-pIQI9 is a D-amino acid pocket-specific phage-displayed peptides were synthe-
sized using D-amino acids. The D-peptides are denotedversion of GCN4-pIQI that contains the same surface
mutations as IQN17 and lacks the pocket residues en- D10-p1 through D10-p12, corresponding to the mirror
images of the φ10-p1 through φ10-p12 sequences (fortirely, while D-IQN17(G572W) contains a tryptophan in
the position corresponding to Gly-572 of gp41, thereby a total of nine D-peptides; three of the phage peptides
were not pocket specific and were therefore not studiedintroducing a large protrusion into the pocket.
Bacteriophage fd expressing a library of L-amino acid further). The peptides (Figure 3C) were synthesized with
blocked termini (acetylated on the N terminus and end-peptides fused to the N terminus of the gene III protein
were utilized. The phage-expressed peptides (Schu- ing in a C-terminal amide) and were oxidized to permit
disulfide bond formation. In addition, two flanking resi-macher et al., 1996) contain ten randomly encoded
amino acid residues flanked by either a cysteine or a dues from the gene III protein were included on each
end of each peptide so as to resemble more closely theserine on both sides (Figure 3C). After several rounds
D-Peptide Inhibitors of HIV-1 Entry
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peptide on the surface of the phage. To increase water
solubility of the D-peptides, many were synthesized with
additional N-terminal lysines (see Experimental Proce-
dures). Most experiments described here were per-
formed using D-peptides with two N-terminal lysines
(denoted with the suffix ª-2Kº). However, in several of
the experiments other variants were employed including
those with no lysines (for example D10-p1 in the X-ray
crystallography studies) and those with four lysines (de-
noted with the suffix ª-4K,º for example D10-p5-4K in
the NMR experiments).
Cell/cell fusion assays, in which cells expressing HIV-1
envelope glycoprotein are mixed with cells expressing
CD4 and coreceptor, were performed in the presence
of these nine peptides. The eight peptides sharing the
consensus sequence inhibit cell/cell fusion with IC50 val-
ues (50% inhibitory concentration) in the micromolar
concentration range, ranging from 3.6 mM for D10-p5-2K
to 130 mM for D10-p12-2K (Figure 4). The ninth sequence
was toxic to cells at comparable concentrations and did
not show inhibitory activity at lower concentrationsÐit
was not studied further (D. M. E. and P. S. K., unpub-
lished results). The D-peptides were also tested for their
ability to inhibit HIV-1 infection of cells, using a recombi-
nant luciferase-based HIV-1 infection assay (Chen et al.,
1994). All of the peptides tested show inhibition of HIV-1
entry into cells, again in the micromolar concentration
range (Figure 4C).
In order to assess the effect of the added lysines,
D-peptides with different numbers of lysines were com-
pared in the cell/cell fusion assay (Figure 4C). D10-p1-
2K, D10-p4-2K, and D10-p6-2K were found to have IC50
values for inhibition of cell/cell fusion (i.e., syncytia for-
mation) approximately 1.5- to 2-fold higher than the re-
spective variants without added lysines. The IC50 values
for inhibition of syncytia formation of D10-p5-4K was
approximately 1.5-fold higher than D10-p5-2K. We con-
clude that the addition of N-terminal lysine residues to
the D-peptides results in only a modest decrease in
inhibitory activity.
The pocket-binding phage sequences always contain
cysteines in the flanking regions (Figure 3C), even
though the library contains either cysteines or serines
at these positions, strongly suggesting that an intramo-
lecular disulfide bond is required for pocket binding and
viral inhibition by these D-peptides. To more directly
Figure 4. Inhibition of HIV-1 Membrane Fusion by D-Peptidesaddress this issue, a derivative of D10-p5-2K in which
each cysteine was replaced with alanine was evaluated (A) Photographs of cell culture assays of fusion between CHO cells
expressing HIV-1 envelope (Kozarsky et al., 1989) and CD4-HeLain the cell/cell fusion assay. Although toxic to cells at
cells with a b-galactosidase reporter gene (Kimpton and Emerman,concentrations above 50 mM, this control peptide did
1992). Cells were cocultured in the absence or presence of D10-not noticeably inhibit syncytia formation up to this con-
p5-2K, and then incubated with b-galactosidase substrate. Multinu-
centration (D. M. E. and P. S. K., unpublished results). cleated cells (syncytia) are stained in blue.
Since D10-p5-2K has an IC50 of 3.6 mM (Figure 4C), we (B) Results from individual cell±cell fusion assays. The number of
conclude that the disulfide bond is crucial for the inhibi- syncytia is plotted as a function of D-peptide concentration.
(C) IC50 values for inhibition of cell/cell fusion as determined by thetory activity of these D-peptides.
syncytia assay described in (A) and of HIV-1 infection as determined
by a recombinant luciferase assay (Chen et al., 1994). For the inhibi-
Crystal Structure of the IQN17±D10-p1 Complex tion of syncytia, average values from four to six determinations are
We obtained diffraction quality crystals of D10-p1 bound given (standard errors of approximately 610%). For inhibition of
to IQN17 using the hanging-drop vapor diffusion method. virus infection, average values from two to five determinations are
given (standard error of approximately 620%).The structure of the complex was solved by multiwave-
length anomalous dispersion (MAD) analysis (for review,
Hendrickson, 1991) of an osmium derivative. The final
structure was refined against data to 1.5 AÊ from a native
Cell
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Table 1. Crystallographic and Refinement Statistics
Data Collection
Crystal l (AÊ ) Completeness (%) Rsyma (%) Resolution (AÊ )
IQN17/D10-p1 1.1197 93.8 4.8 1.5
Os l1 1.1403 98.6 6.3 2.0
Os l2 1.1399 96.8 9.7 2.0
Os l3 1.1393 96.9 7.9 2.0
Os l4 1.1197 97.0 8.4 2.0
MAD Phasing Statistics (22.0±2.0 AÊ )
Rcullisc Rcullisc Rcullisc Ph. Powerd Ph. Powerd
Derivative Risob (%) (Acentric) (Centric) (Anom.) (Acentric) (Centric) Occ.e Anom. Occ.e
Os l1 vs. l4 7.3 0.75 0.61 0.47 1.41 1.21 20.039 0.337
Os l2 vs. l4 5.2 0.83 0.71 0.44 1.04 1.15 20.027 0.533
Os l3 vs. l4 3.3 0.97 0.97 0.49 0.35 0.28 20.005 0.295
Overall figure of merit (before solvent flattening): 0.68
Refinement Statistics
Rms Deviations
Non-hydrogen Reflections
Crystal protein atoms Waters Ions Resolution (AÊ ) (Total) Rcrystf Rfreef Bonds (AÊ ) Angles (8)
IQN17/D10-p1 516 150 1 10.0±1.5 13,549 0.214 0.245 0.012 1.498
a Rsym 5 SSj|Ij 2 kIl|/SSj|kIl|, where Ij is the recorded intensity of the reflection j and kIl is the mean recorded intensity over multiple recordings.
b Riso 5 S||F(li) 6 F(l4)| 2 |F(li)||/S|F(l4)|, where F(li) is the structure factor at wavelength li and F(l4) is the structure factor at the reference wave-
length l4.
c Rcullis 5 S||F(li) 6 F(l4)| 2 |Fh(li),c||/S|F(li) 6 F(l4)|, where Fh(l4),c is the calculated heavy atom structure factor.
dPhase power 5 kFh(li)l/E, where kFh(li)l is the root-mean-square heavy atom structure factor and E is the residual lack of closure error.
e Occupancies are values output from MLPHARE.
fRcryst, Rfree 5 S||Fobs| 2 |Fcalc||/|Fobs|, where the crystallographic and free R factors are calculated using the working and test sets, respectively.
Test set contained 10% of reflections.
crystal to a crystallographic R factor of 21.4% with an (Trp-10, Trp-12, and Leu-13) or invariant from the original
flanking phage sequence (Gly-1, Ala-2, and Ala-16). TheRfree of 24.5% (Table 1). The electron density map at this
resolution reveals structural details of IQN17 and D10- side chains of Trp-10, Trp-12, Leu-13, and Ala-16 are
deeply buried in the hydrophobic pocket of IQN17. Gly-1p1 with clarity (Figure 5C). IQN17 is a continuous, regular
three-stranded coiled coil (Figure 5A). Structural super- and Ala-2 are not deeply buried but also contact the
indole group of Trp-571 in the pocket. (For the gp41-position indicates that the overall architecture of the HIV-1
gp41 hydrophobic pocket in the IQN17/D10-p1 complex derived residues of IQN17, we use the residue numbers
corresponding to those in the HXB2 strain of HIV-1is almost identical to that in the wild-type HIV-1 gp41
structure (Chan et al., 1997), with a Ca rmsd of 0.65 AÊ . gp160.) Although the interface between D10-p1 and
IQN17 is largely nonpolar, a hydrogen bond is formedThe conformation of the GCN4-pIQI fraction of the mole-
cule is also well preserved, with a Ca rmsd from the between a pocket residue and D10-p1: Gln-577 Oe1±Trp-
12 Ne1 (2.8 AÊ ). The potential exists for a second intermo-original GCN4-pIQI (Eckert et al., 1998) of 0.40 AÊ .
As anticipated from our binding studies (Figure 3B), lecular hydrogen bond (Gln-577 Ne2±Glu-9 O; 3.1 AÊ ) with
less ideal geometry. It is not apparent why Glu-9 isD10-p1 is bound only to the gp41 region of IQN17 (Fig-
ures 5A and 5B). A disulfide bond in D10-p1 between absolutely conserved (Figure 3C), although its side chain
carboxylate does bend back to accept a hydrogen bondCys-3 and Cys-14 results in a somewhat circular overall
structure. Two segments of this D-peptide, Ala-2 to Ala-5, from its own backbone amide (2.7 AÊ ), and both of its
methylene groups contact the d1-methyl of Leu-581.and Ala-11 to Ala-16, form short left-handed a helices,
and the residues between these two segments form a The identities of the conserved D-peptide pocket-
binding residues (Trp-10, Trp-12, and Leu-13) are veryloop. Two of the loop residues (Arg-8 and Glu-9) are
also in a left-handed helical conformation. The longer similar to those of C34 (Trp-628, Trp-631, and Ile-635).
However, only the indole rings of Trp-10 (D10-p1) and(C-terminal) helical segment of D10-p1 binds the gp41
pocket of IQN17 in an oblique manner, at a similar angle Trp-628 (C34) occupy the same position when bound
to the gp41 pocket (Figure 6). The packing differencesto the packing of the HIV-1 C34 helix against the N36
peptide coiled coil (Chan et al., 1997). In a superposition of the Trp-12 and Leu-13 side chains (relative to Trp-631
and Ile-635 in C34) are accompanied by slight changes inof the two crystal structures, the overall positions of
the D10-p1 and C34 helices closely overlap, but the the shape of the pocket: (1) Lys-574, lining the left side
of the pocket (in the orientation shown in Figure 6), isorientations of most side chains are significantly differ-
ent, owing to the opposite handedness of the inhibitors pushed out, widening the pocket as compared to the
N36/C34 structure; (2) Gln-577, lining the bottom, pushes(Figure 6).
Of the 16 residues in D10-p1, only 6 interact directly further into the pocket, raising the bottom wall (mainly
due to a rotation about x2); and (3) a rotamer change ofwith the gp41 pocket of IQN17 (Figure 5B). These resi-
dues are either part of the conserved EWXWL sequence Leu-565 slightly lowers the top wall of the pocket.
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Figure 5. Crystal Structure of a D-Peptide Bound to the gp41 Pocket
(A) Ribbon representation of the overall structure of the IQN17/D10-p1 complex. The GCN4-pIQI9 part of the chimera (dark blue) and the HIV-1
gp41 hydrophobic segment (gray) form a continuous three-stranded coiled coil. Three D10-p1 inhibitors (purple and green) bind solely to the
hydrophobic pocket. The six residues of the D-peptide that make direct contact with IQN17 are shown in green (Gly-1, Ala-2, Trp-10, Trp-12,
Leu-13, and Ala-16). Figure drawn with Insight II 98.0 (Molecular Simulations Inc.).
(B) Stereo view of the IQN17/D10-p1 complex in which IQN17 is represented as a molecular surface and D10-p1 is represented with sticks.
The color scheme is as in (A). The four conserved residues of the EWXWL motif (Glu-9, Trp-10, Trp-12, and Leu-13) are labeled. Figure drawn
with Insight II 98.0 (Molecular Simulations Inc.).
(C) Stereo view of a region of the final 1.5 AÊ 2Fo-Fc map, contoured at 2.1s, superimposed on the final model. The view is approximately the
same orientation as in (B). Figure drawn with O (Jones et al., 1991).
Overall, however, the hydrophobic pocket maintains its of these residues among the selected phage sequences,
strongly suggest that the D-peptides all bind in a similarintegrity between the N36/C34 and IQN17/D10-p1 struc-
tures (Figure 6). manner. To more directly address this issue, NMR ex-
periments were used to assess the binding of each
D-peptide to IQN17. In the cocrystal structure, Trp-10NMR Studies of the IQN17/D±Peptide Complexes
The finding that Trp-10, Trp-12, and Leu-13 of D10-p1 of D10-p1 and Trp-571 of IQN17 are oriented in a manner
that should alter the chemical shifts of several protonsare buried in the IQN17 pocket, and the conservation
Figure 6. Comparison of the Pocket in the
C34 and D10-p1 Bound States
Stereo view of the structural superposition
between IQN17/D10-p1 (green) and HIV-1 N36/
C34 (red) structures in the region of the hy-
drophobic pocket. Two of the pocket-binding
residues of D10-p1 (Trp-12 and Leu-13) differ
in position from two of the pocket-binding
residues of C34 (Trp-631 and Ile-635), whereas
Trp-10 of D10-p1 and Trp-628 of C34 are
closely overlaid. In addition, several residues
comprising the hydrophobic pocket occupy
slightly different positions in the two struc-
tures (Leu-565, Gln-577, Lys-574, as labeled).
Figure drawn with Insight II 98.0 (Molecular
Simulations Inc.).
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Figure 7. NMR Indicates a Similar Mode of
Binding for Many D-Peptides
(A) One-dimensional 1H NMR spectra of D10-
p1-2K (top), IQN17 (middle), and a 1:1 com-
plex of D10-p1-2K and IQN17 (bottom). The
x axis is the same as for (B) below. The upfield
peaks assigned to four aromatic ring protons
of Trp-571 are indicated. The unmarked up-
field peak of the bottom trace corresponds
to an unassigned Ha resonance.
(B) Two-dimensional TOCSY NMR spectrum
of the IQN17/D10-p1-2K complex. Cross-
peaks linking the same Trp-571 protons are
indicated, along with specific assignments.
No other type of side chain is expected to
display this cross-peak pattern in this chemi-
cal shift range.
(C) One-dimensional 1H NMR spectra of 1:1
complexes between IQN17 and each D-pep-
tide (as labeled). The same four protons from
Trp-571 (assigned in separate TOCSY and
NOESY experiments) are indicated in each
spectrum. Some upfield-shifted peaks are se-
lectively broadened compared to others in
the same spectra, especially for the complex
with D10-p5-4K, suggestive of a chemical ex-
change process.
due to aromatic ring current effects (Bovey, 1988). Spe- D10-p10-2K, and D10-p12-2K) the D-peptides contact
the hydrophobic pocket with very similar binding inter-cifically, use of the structure-based chemical shift pre-
diction program SHIFTS (Osapay and Case, 1991) pre- faces, bringing Trp-571 in close contact with the aro-
matic ring of Trp-10 in roughly the same orientation.dicted that four protons of the Trp-571 indole (Hz2, Hh2,
Hz3, and He3) would experience a significant upfield shift, For the complexes with D10-p5-4K and D10-p7-2K, this
conclusion also seems very likely, although the moreespecially the Hz3 proton (P. A. C. and P. S. K., unpub-
lished results). Figure 7A demonstrates these effects: limited chemical shift dispersion and broader peaks
raise the possibility of some other mode of binding.the aromatic region of the IQN17/D10-p1-2K NMR
spectrum displays chemical shifts dramatically different
from either of the two separate components, including Discussion
a set of upfield peaks. A two-dimensional TOCSY experi-
ment was used to confirm that the upfield peaks all Validation of the gp41 Pocket as a Target
for Drug Developmentcorrespond to a single Trp indole (Figure 7B).
If each D-peptide binds the IQN17 pocket in the same Inhibition of HIV-1 infection by synthetic C-peptides,
and structural studies of gp41, have shed light on thefashion as D10-p1, a similar juxtaposition of Trp-571
and Trp-10 should occur, also resulting in upfield-shifted vulnerable but transient prehairpin intermediate of the
envelope glycoprotein during the viral entry process.peaks. All of the IQN17/D-peptide complexes studied
displayed such peaks (Figure 7C). Although there is sub- Several lines of evidence suggest that the C-peptides
act in a dominant-negative manner by binding to thisstantial variation in the magnitudes of these changes,
ranging from roughly 0.5 to 2 ppm for the most upfield- prehairpin intermediate (Figure 1). First, the C-peptides
must be present during the infection process to actshifted proton (Hz3, in all cases where it could be as-
signed), ring current effects can be highly sensitive to as inhibitors. Preincubation of virus with a C-peptide,
followed by its removal, does not inactivate the virusdistance and orientation. Moreover, the magnitudes of
these changes are very large. By comparison, chemical (Furuta et al., 1998). Second, the inhibitory potency of
C-peptides is greatly reduced in the presence of anshift differences used to detect binding in studies of
SAR (structure±activity relationships) by NMR (Shuker equimolar amount of complementary N-peptides (Lu et
al., 1995; see also Chen et al., 1995). Third, C-peptideet al., 1996) are frequently much smaller, in the range
of 0.05 to 0.2 ppm. Two-dimensional (2D) TOCSY experi- derivatives that have weakened interactions with N-pep-
tides show decreased potency as inhibitors (Wild et al.,ments confirm that the upfield-shifted aromatic peaks
of each complex belong to a single indole side chain, 1995; Chan et al., 1998). Fourth, interaction between
gp41 and a C-peptide has been demonstrated in immu-almost certainly Trp-571. For several of the complexes
studied, 2D NOESY experiments also indicate contact noprecipitation experiments. Importantly, this interac-
tion is detected only after exposure of the envelopebetween this side chain and another aromatic group,
presumably Trp-10 (P. A. C., D. M. E., and P. S. K., complex to cellular receptors (Furuta et al., 1998).
Despite the antiviral effect of synthetic C-peptides,unpublished results).
We conclude that in the majority of these IQN17 com- orally bioavailable small molecules are more desirable.
Small molecules that bind to the hydrophobic pocket ofplexes (i.e., D10-p1-2K, D10-p3-2K, D10-p4, D10-p6,
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the gp41 core might be expected to function as in- Toward Small-Molecule Inhibitors
Our results also make possible the rapid discovery ofhibitors in the same dominant-negative manner as the
other drug candidates with the same mechanism of ac-C-peptides (Chan et al., 1997). Recent mutagenesis
tion as the D-peptides identified here, but with com-studies on C34 demonstrate that the hydrophobic resi-
pletely unrelated chemical structures. In particular, adues that insert into this pocket are important for inhibi-
molecule that accurately presents the gp41 hydrophobictory potency, reinforcing the suggestion that the gp41
pocket (e.g., IQN17) either alone or in combination withpocket is an attractive drug target (Chan et al., 1998).
a pocket-binding molecule (e.g., D10-p1) constitutesNonetheless, this hypothesis had not been tested di-
the basis for high-throughput drug discovery screens.rectly, and another potent C-peptide, DP178 (or T-20),
Chemical libraries can be screened with IQN17 to iden-lacks these pocket binding residues entirely (Kilby et al,
tify pocket-binding molecules. Alternatively, drug candi-1998).
dates can be identified by their ability to disrupt theOur finding that D10-p1 inhibits HIV-1 infection and
interaction between IQN17 and a D-peptide.binds exclusively to the gp41 pocket (as shown by X-ray
crystallography) demonstrates directly that molecules
that bind solely to the pocket can inhibit infection. The Implications for Vaccine Candidates
size of this pocket (approximately 400 AÊ 3) makes it ideal Finally, the strategy used to create a soluble, trimeric
for binding by a small molecule. Thus, validation of the version of a part of the gp41 N-terminal coiled-coil region
gp41 hydrophobic pocket as a target for drug discovery may also help efforts to develop HIV vaccine candidates.
sets the stage for the development of a new class of Recent studies have raised the possibility that tran-
siently exposed conformations of proteins required fororally bioavailable anti-HIV drugs that inhibit viral entry
HIV-1 entry can be useful for eliciting a neutralizing anti-into cells. These drugs would be a useful addition to
body immune response (LaCasse et al., 1999). It is possi-the current regimen used to treat HIV-1 infection. Such
ble that the transiently exposed prehairpin intermediatedrugs would also demonstrate the feasibility of small-
is a vulnerable target for neutralizing antibodies. Themolecule therapeutics that interfere with protein±protein
most obvious approach toward eliciting an antibody re-interactions (as opposed to enzyme activity).
sponse against the N-helix region of gp41 would be to
use an N-peptide as an immunogen. However, since
the isolated N-peptides aggregate, they do not properlyD-Peptides and Derivatives as Inhibitors
present the gp41 N-helix coiled-coil trimer. Accordingly,of HIV Entry
the same strategy used here to solve the aggregationThe D-peptides identified here can serve as starting
problem for the gp41 hydrophobic pocket can be em-points for the development of therapeutic or prophylac-
ployed to develop soluble, trimeric versions of the gp41tic agents that inhibit HIV entry. However, the potency
N-helix coiled-coil region that might have utility as immu-of these D-peptides is only in the micromolar range
nogens.(Figure 4C). For comparison, C34 and T-20 each have
nanomolar potency (in cell culture), but they are subject
Experimental Proceduresto proteolysis and are large in size (z35 residues). The
D-peptides are also larger than desired for oral adminis-
Phage Displaytration ($16 residues). In contrast, cyclosporin, an effec-
Bacteriophage fd expressing a library of ten randomly encoded
tive oral pharmaceutical, is a cyclic 11-residue peptide amino acids flanked by Ser or Cys residues on the N terminus of
composed of D-amino acids and N-methylated amino the pIII protein (Schumacher et al., 1996) were utilized here (Figure
3C). The expressed fusion protein contains an N-terminal Ala-Asp-acids. Thus, chemical optimization of these D-peptide
Gly-Ala sequence preceding the peptide library sequence. The am-HIV inhibitors may lead to derivatives that are directly
plified phage stock had a titer of approximately 1012 transducinguseful as therapeutic agents.
units per milliliter, consisting of 3.6 3 108 primary clones.
Several considerations suggest that it may be possi- Neutravidin (Pierce, 10 mg in 100 ml of 100 mM NaHCO3) was
ble to improve the potency and reduce the size of these added to individual wells of a 96-well high-binding styrene plate
D-peptides. First, mirror-image phage display experi- (Costar) and incubated overnight on a rocking platform at 48C. The
neutravidin was removed, and the wells were washed four timesments utilize only the 20 naturally occurring amino acid
with a TBS/Tween solution (50 mM Tris [pH 7.5], 150 mM NaCl,residues, leaving a tremendous range of chemical diver-
0.5% Tween-20). Biotinylated D-IQN17 (100 ml of a 10 mM peptidesity unsampled for both the side chains and the back-
solution in 100 mM NaHCO3) was added to the wells and incubated
bone. Second, several of the remaining residues are for 1 hr at 258C. The biotinylated target was removed, and a blocking
involved in a loop remote from the pocket (Figure 5B). solution (30 mg/ml nonfat dried milk in 100 mM NaHCO3, freshly
made) was added to the wells and incubated for 2 hr, with rocking,Third, IQN17, alone or in combination with a specific
at 48C. The blocking solution was removed, and the wells werepocket-binding molecule (e.g., D10-p1), greatly facili-
coated again with the biotinylated target as above. The target wastates the ease with which more sophisticated drug dis-
removed, and the unliganded neutravidin was blocked by the addi-
covery methods (e.g., utilizing combinatorial libraries tion of the blocking solution with 5 mM biotin. After removing the
based on these D-peptides) can be employed to dis- biotin, the wells were washed six times with the TBS/Tween solution.
The phage stock (Schumacher et al., 1996) was then added to thecover better inhibitors. Fourth, the NMR assay employed
wells (50 ml of phage stock plus 50 ml of phage-binding buffer: TBShere can be used as a fast screen to verify that variants
[50 mM Tris pH 7.5, 150 mM NaCl], 0.1% Tween-20, 1 mg/ml nonfatbind the gp41 hydrophobic pocket in a similar manner
dried milk, 0.05% sodium azide). The incubation time of the phage
as the lead D-peptides (cf. Shuker et al., 1996). Finally, stock in the wells decreased with increasing rounds of selection.
the availability of a high-resolution cocrystal structure For the first round, the phage were incubated in the wells for 24
hr, and in the seventh round, they were incubated for 12 hr. Afterenables rational drug development approaches.
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incubation, the phage solution was removed, and the wells were recognition site. Similarly, D-GCN4-pIQI9 and D-IQN17(G572W) were
synthesized with biotinylated N termini and Gly-Lys-Gly linkers.washed with TBS/Tween to remove the unbound phage. In the first
round, the wells were washed six times with no incubation. In follow- D-peptides corresponding to the mirror images of the phage-
displayed sequences that bound D-IQN17 were synthesized withing rounds, the wells were washed twelve times; the odd-numbered
washes were performed quickly, with no incubation time; even- two flanking residues on each end. These residues (GA at the N
terminus and AA at the C terminus) correspond to the mirror imagesnumbered washes were incubated for increasing amounts of time
each round of phage selection (round 2, no incubation; round 3, 3 of phage-encoded sequences that flank the expressed peptide se-
quences. In addition, in order to improve water solubility for themin; round 4, 5 min; round 5, 7 min; round 6, 10 min, round 7, 12
min). In the first round, phage were eluted by acid elution (0.1 N HCl membrane fusion inhibition studies and NMR studies, multiple D-Lys
residues were added at the N termini of the D-peptides. Peptide[pH 2.2], and 1 mg/ml BSA were added to the wells and incubated
for 15 min at 48C). In all subsequent rounds, the phage were eluted variants with two N-terminal lysines are denoted with the suffix
ª-2K,º and peptides with four N-terminal lysines are denoted withby the addition of 2 mg of trypsin (Sigma, T-8658) in 100 ml of phage-
binding buffer and 2.5 mM CaCl2 with 1 hr incubation at 378C. To ª-4K.º
After cleavage from the resin, peptides were desalted on a Sepha-determine recovery, a dilution of the eluted phage was used to infect
K91-kan cells. After a 1 hr incubation, 100 ml of cells was removed dex G-25 column (Pharmacia) in 5% acetic acid, purified by reverse-
phase high-performance liquid chromatography (Waters, Inc.) on aand 1:10, 1:100, and 1:1000 dilutions in LB were plated on LB/
tetracycline plates. Phage recovery was determined as a ratio of Vydac C18 preparative column, using a water-acetonitrile gradient
in the presence of 0.1% trifluoroacetic acid, and lyophilized. D-peptidestransducing units recovered (the titer of the eluted phage) to the
input number of transducing units (the titer of the phage stock used were also air oxidized by dissolving the lyophilized powder in 20
mM Tris (pH 8.2) and stirring at room temperature for several days.that round). Nonspecific phage recovery generally has a ratio in the
order of magnitude of 1028 to 1029, whereas specifically amplified Oxidized peptides were then HPLC purified again. The expected
molecular weights of all peptides were verified using MALDI-TOFphage have a ratio of 1027 or greater. Individual clones were ampli-
fied and sequenced. mass spectrometry (PerSeptive Biosystems).
φ10-p7 was identified after five rounds, and φ10-p1, φ10-p3,
φ10-p4, φ10-p5, and φ10-p6 after seven rounds of phage selection. Circular Dichroism
The phage selection was performed a second time, with shorter CD experiments were performed on an Aviv 62A DS circular dichro-
incubation times, using the phage eluted from round 2. The incuba- ism spectrometer. Measurements from 200 to 260 nm were per-
tion times were shortened to 6 hr for round 3, 2 hr for round 4, and formed on a 10 mM solution of IQN17 in PBS (50 mM sodium phos-
1 hr for round 5. φ10-p10 and φ10-p12 were identified after these phate, 150 mM NaCl [pH 7.4]) in a 10 mm path length cuvette.
three additional rounds of selection.
To test the specificity of binding of identified phage clones to the Sedimentation Equilibrium
pocket of D-IQN17, the phage clones were added to wells of 96- Sedimentation equilibrium experiments were performed on a Beck-
well plates coated as above with either D-IQN17, D-GCN4-pIQI9, man XL-A analytical ultracentrifuge using an An-60 Ti rotor. A stock
D-IQN17(G572W), or wells with no target (Figure 3B). The phage of IQN17 at approximately 200 mM was dialyzed overnight against
were incubated on the plates and washed for the same lengths of PBS (pH 7.0), and the concentration was redetermined following
time as in the round from which they were identified. Eluted phage dialysis (Edelhoch, 1967). The sample was diluted to 20 mM using
were used to infect K91-kan cells, and the recovered transducing the dialysis buffer. The sample was spun at 22,000 and 24,000 rpm;
units were determined as above. Seven of the ten phage clones approximately 18 hr after starting, or changing centrifugation speed,
were shown to bind specifically to D-IQN17. Two additional phage the absorbance was recorded at 230 nm.
clones, φ10-p10 and φ10-p12, were not tested in this binding assay
but were expected to bind specifically to D-IQN17 because they
Cell/Cell Fusion Assay
shared the same consensus sequence as six of the D-IQN17 specific
Inhibition of cell/cell fusion (i.e., syncytia formation) was assayed
phage clones.
by coculturing Chinese hamster ovary (CHO) cells expressing HXB2
envelope, tat and rev (Kozarsky et al., 1989), and HeLa-CD4-LTR-
Beta-gal cells (M. Emerman, National Institutes of Health AIDSPeptide Purification
Reagent Program) in the presence of varying concentrations ofIQN17 (and all variants) and the D-peptides were synthesized on a
D-peptide. When these cells are mixed in the absence of an inhibitor,Perkin Elmer Model 431A peptide synthesizer upgraded with con-
they form syncytia, or multinucleated cells, which express b-galac-ductivity feedback monitoring. All of the peptides have an acetylated
tosidase (Kimpton and Emerman, 1992). Peptide stocks for theseN terminus and a C-terminal amide and were synthesized using
assays were prepared at approximately 20 mM in DMSO, and theFmoc/HBTU chemistry (Fields et al., 1991) modified with DMSO/
precise concentrations were determined using tyrosine, tryptophan,NMP resin swelling and acetic anhydride capping. In all syntheses
and cysteine absorbance at 280 nm in 6 M GuHCl (Edelhoch, 1967).involving D-Ile or D-Thr, which have second chiral centers, the exact
These stocks were diluted in media to the concentrations requiredmirror images of the naturally occurring L-Ile or L-Thr were used
for the experiment (ranging from 2.5 mM to 200 mM); the final concen-(D-allo-Ile and D-allo-Thr). The peptides were cleaved from the resin
tration of DMSO was kept constant at 1%. The peptide sample wasusing Reagent K (King et al., 1990).
added to wells of an 8-well permanox chamber slide (Lab-Tek), andIQN17 contains 29 residues derived from GCN4-pIQI on the N
an estimated 2 3 104 CHO cells and 4 3 104 HeLa cells were thenterminus and 17 residues from the C terminus of N36 on the C
added. Approximately 20 hr after coculturing the cells, the mono-terminus. There is a 1 residue overlap between GCN4-pIQI and the N36
layers were stained with 5-bromo-4-chloro-3-indolyl-b-D-galacto-region, making the peptide 45 residues long. To improve solubility,
side to detect the syncytia, which were visualized by microscopethree amino acid substitutions were made in the GCN4-pIQI region
and counted manually. (The entire well was counted; a syncytiumof IQN17, as compared to the original GCN4-pIQI sequence (Eckert
was scored as a fused cell containing three or more nuclei.) Theet al., 1998). These substitutions are L13E, Y17K, and H18K. Thus,
IC50 was calculated from fitting the data to a Langmuir equation [y 5the sequence of IQN17 is Ac±RMKQIEDKIEEIESKQKKIENEIARIKK
k/(1 1 [peptide]/IC50)], where y 5 number of syncytia, and k is aLLQLTVWGIKQLQARIL±NH2 (Ac± represents an N-terminal acetyl
scaling constant.group, and ±NH2 represents a C-terminal amide; the HIV portion is
underlined.)
For mirror-image phage display, D-IQN17 was synthesized using HIV Infectivity Assay
The ability of the D-peptides to inhibit HIV-1 infection was assayedD-amino acids. Protected D-amino acids were obtained from Pep-
tides International and Bachem Bioscience. The N terminus of the using a recombinant luciferase-encoding HIV-1 (Chen et al., 1994).
As in the cell/cell fusion assays, peptide stocks were prepared inpeptide was biotinylated prior to cleavage from the resin, using
NHS-LC-biotin II (Pierce, catalog #21336). Between the biotin and DMSO. The final concentration of DMSO was kept constant at 1%.
The virus was produced by cotransfecting an envelope-deficientthe IQN17 sequence was a three±amino acid linker (Gly-Lys-Gly),
with the lysine in the naturally occurring L-form for use as a trypsin HIV-1 genome NL43LucR2E2 (Chen et al., 1994) and the HXB2 gp160
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expression vector pCMVHXB2 gp160 (D. C. Chan and P. S. K., simulated annealing omit maps and with the program WHAT-CHECK
(Hooft et al., 1996).unpublished data; see Chan et al., 1998) into 293T cells. Low-speed
centrifugation was used to clear the viral supernatants of cellular All residues of IQN17 and of D10-p1 (when converted into its
mirror image) occupy most preferred areas of the Ramachandrandebris. The supernatant was used to infect HOS-CD4/Fusin cells
(N. Landau, National Institutes of Health AIDS Reagent Program) in plot. The conformations of the majority of the residues are well
defined except for the two most N-terminal residues of IQN17 andthe presence of the D-peptides with concentrations ranging from 0
to 500 mM. Forty-eight hours postinfection, the cells were harvested, the side chains of Arg-6 and Arg-8 of D10-p1. As in the original
GCN4±pIQI structure (Eckert et al., 1998), a chloride ion is bound inand luciferase activity was monitored using a Wallac AutoLumat
LB953 luminometer (Gaithersburg, MD). The IC50 was calculated the coiled-coil core near the side chains of Gln-16. Its temperature
factor (B 5 45.3 AÊ 2) is higher than those of the interacting nitrogenfrom fitting the data to a Langmuir equation [y 5 k/(1 1 [peptide]/
IC50)], where y 5 luciferase activity, and k is a scaling constant. atoms of Gln-16 (B 5 32.7 AÊ 2) and indicates only partial occupancy.
Crystallization NMR
A 10 mg/ml stock (total peptide concentration) of a mixture of IQN17 1H NMR experiments were performed at 258C on a Bruker AMX
and D10-p1 was prepared in water. The final concentration of IQN17 500 spectrometer. Data were processed with Felix 98.0 (Molecular
was about 1.4 mM, and the final concentration of D10-p1 was about Simulations, Inc.) on Silicon Graphics computers, and all spectra
1.5 mM. Initial crystallization conditions were found using Crystal were referenced to DSS. All samples were dissolved in 100 mM
Kits I and II (Hampton Research) and then optimized. The best NaCl, 50 mM sodium phosphate (pH 7.5); the buffers used were
diffracting crystals grew from 1 ml of the stock added to 1 ml of the .99.7% D2O, to remove overlapping resonances from solvent-
reservoir buffer (10% PEG 4000, 0.1 M sodium citrate [pH 5.6], 20% exchangeable backbone and side chain protons. Solute concentra-
2-propanol) and allowed to equilibrate against the reservoir buffer. tions ranged from 0.3 to 1.0 mM for individual peptides, and from
Crystals belong to the space group P321 (a 5 b 5 41.83 AÊ ; c 5 0.8 to 1.0 mM for 1:1 complexes of IQN17 with each D-peptide.
84.82 AÊ , a 5 b 5 908, g 5 1208) and contain one IQN17/D10-p1 Several samples of IQN17/D-peptide complexes showed slight pre-
monomer in the asymmetric unit. A useful heavy atom derivative cipitation over time. 2D NOESY and TOCSY experiments were per-
was produced by increasing the concentration of PEG 4000 in the formed as described (Cavanagh et al., 1996) on samples of IQN17
reservoir solution by 4%, adding (NH4)2OsCl6 to the reservoir solution and of each complex, with mixing times of 55 ms (NOESY) and 42
to a final concentration of 5 mM and adding 5 ml of the resulting ms (TOCSY). Spectral widths of 11,111 Hz and 5,555 Hz were used in
solution to the drop containing the protein crystal. Prior to data the acquisition (t2) and indirect (t1) dimensions, respectively. TOCSY
collection, native and heavy atom derivative crystals were trans- experiments employed the DIPSI-2rc mixing sequence (Cavanagh
ferred into cryosolution containing 20% PEG 4000, 0.1 M sodium and Rance, 1993). Chemical shift predictions were made using the
citrate (pH 5.6), 20% 2-propanol and flash-frozen using an X-stream program SHIFTS (version 3.02b, D. Sitkoff, K. Osapay, and D. A.
cryogenic crystal cooler (Molecular Structure Corporation). Case; The Scripps Research Institute).
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ited with the ID code 1czq; they are available immediately at the
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